Key result
Among survivors of myocardial infarction, intermittent claudication was associated with an increased risk of death or nonfatal cardiac events.
Why the study?
Does the presence of intermittent claudication predict recurrent cardiac events and mortality in survivors of myocardial infarction?
Cohort (n=1,045)
Does the presence of intermittent claudication predict recurrent cardiac events and mortality in survivors of myocardial infarction?
Intermittent claudication in post-MI patients is a strong independent predictor of recurrent cardiovascular events and mortality, associated with heightened inflammation and underuse of beta-blockers.
Answers are grounded in this paper and cite their sources.
Intermittent claudication may identify higher-risk post-MI survivors; leaves open whether targeted interventions improve outcomes.
BACKGROUND: Among coronary disease patients, concomitant peripheral arterial disease is a potent risk factor for future cardiac events and mortality. We sought to determine clinical and biochemical markers that might better elucidate the relationship between coronary and peripheral arterial disease. METHODS: Two months after an index myocardial infarction, 1045 patients provided detailed medical histories and underwent blood testing for selected hemostatic, lipid, and inflammatory markers. Patients were then followed up prospectively for a mean of 26 months. RESULTS: Compared with individuals without intermittent claudication (n = 966), those with claudication (n = 78) (information was unavailable for 1 individual) were significantly older and demonstrated an increased frequency of diabetes mellitus, tobacco use, prior cardiac and cerebrovascular events, and depressed left ventricular function. Individuals with claudication were less likely to receive beta-blocker therapy after the index infarction. Individuals with claudication had evidence of enhanced procoagulant and proinflammatory states manifested by relative elevations in plasma fibrinogen, D-dimer, C-reactive protein, and serum amyloid A concentrations. During follow-up, the presence of claudication was associated with an independent 2-fold increase in the combined end point of death or nonfatal cardiac event (38.5% vs 17.8%, P =.001) and a 5-fold increase in cardiac mortality (19.2% vs 3.6%, P =.001). Patients with intermittent claudication who were not treated with beta-blockers had a significant 3-fold mortality excess relative to those receiving beta-blockers. CONCLUSIONS: Following myocardial infarction, the added presence of intermittent claudication is associated with heightened procoagulant and proinflammatory states and an underuse of beta-blocker therapy and is a strong independent predictor of recurrent cardiovascular events.
No takes yet. Share an insight, caveat, or question.
Craig R. Narins (2004) conducted a cohort in Myocardial Infarction (n=1,045). Intermittent claudication vs. No intermittent claudication was evaluated on combined end point of death or nonfatal cardiac event (p=.001). Among survivors of myocardial infarction, intermittent claudication was associated with an increased risk of death or nonfatal cardiac events.
Synapse has enriched 10 related papers. Consider them for comparative context: